Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations

Background and Objectives: Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) are effective first-line chemotherapeutic agents for patients with advanced non-small-cell lung cancer (NSCLC) harboring drug-sensitive EGFR mutations. However, the effectiveness of EGFR-TKI rechalleng...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Yutaka, Imai, Hisao, Sugiyama, Tomohide, Minemura, Hiroyuki, Kanazawa, Kenya, Kasai, Takashi, Minato, Koichi, Kaira, Kyoichi, Kaburagi, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466413/
https://www.ncbi.nlm.nih.gov/pubmed/34577852
http://dx.doi.org/10.3390/medicina57090929

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466413/
https://www.ncbi.nlm.nih.gov/pubmed/34577852
http://dx.doi.org/10.3390/medicina57090929

Ejemplares similares